Advertisement

Forensic Toxicology

, Volume 32, Issue 1, pp 82–88 | Cite as

Synthetic cannabinoids abused in South Korea: drug identifications by the National Forensic Service from 2009 to June 2013

  • Heesun Chung
  • Hyeyoung Choi
  • Sewoong Heo
  • Eunmi Kim
  • Jaesin Lee
Original Article

Abstract

The rapid increase in the number of new psychoactive substances and their abuse is the most recent drug abuse issue worldwide. Although abuse of synthetic cannabinoids is highly restricted in South Korea, the rapid increase in the number of new substances is forcing the legal regulation authority to continuously improve the drug regulation act. As a result of drug screening by the National Forensic Service from 2009 to June 2013, 26 species of synthetic cannabinoids were identified in materials seized mainly by the Police Agency and the Prosecutor’s Office in South Korea. One of the most remarkable trends in synthetic cannabinoids is the increase in halogenated derivatives and new substances, including UR-144 and A-836,339 originally developed as analgesics by Abbott Laboratories. The N-pentyl fluorinated analog of UR-144 (XLR-11) has become the most frequently found synthetic cannabinoid in 2013 since its first appearance in 2012, whereas abuse of A-836,339 analogs has been little reported despite their abuse potential. Until early 2011, nicotine was the most frequently found active coingredient with synthetic cannabinoids. However, various psychoactive substances such as Δ9-tetrahydrocannabinol, α-pyrrolidinobutiophenone, α-pyrrolidinovalerothiophenone, and N,N-diallyl-5-methoxytryptamine have often been found as coingredients in herbal highs since late 2011. These coingredients should also be systematically regulated, because they can cause unexpected side effects. It is suggested that authorities in different countries share information about synthetic cannabinoids and their coingredients.

Keywords

New psychoactive substance Synthetic cannabinoids XLR-11 Coingredients National Forensic Service South Korea 

Notes

Acknowledgments

This study was supported by funding from the National R & D Program of the Ministry of Education, Science, and Technology (2012-0009836) and the National Forensic Service of Korea.

Conflict of interest

There are no financial or other relations that could lead to a conflict of interest.

References

  1. 1.
    EMCDDA (2011) Annual report on the state of the drugs problem in Europe. European Monitoring Centre for Drugs and Drug Addiction, LisbonGoogle Scholar
  2. 2.
    Hillebrand J, Olszewski D, Sedefov R (2010) Legal highs on the internet. Subst Use Misuse 45:330–340PubMedCrossRefGoogle Scholar
  3. 3.
    Uchiyama N, Kikura-Hanajiri R, Kawamura M, Goda Y (2009) Identification of a cannabimimetic indole as a designer drug in a herbal product. Forensic Toxicol 27:61–66CrossRefGoogle Scholar
  4. 4.
    Auwärter V, Dresen S, Weinmann W, Müller M, Pütz M, Fereirós N (2009) ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832–837PubMedCrossRefGoogle Scholar
  5. 5.
    UNODC (2012) World drug report 2012. United Nations Office on Drugs and Crime, ViennaGoogle Scholar
  6. 6.
    Kikura-Hanajiri R, Uchiyama N, Kawamura M, Goda Y (2013) Changes in the prevalence of synthetic cannabinoids and cathinone derivatives in Japan until early 2012. Forensic Toxicol 31:44–53CrossRefGoogle Scholar
  7. 7.
    Zuba D, Byrska B (2013) Analysis of the prevalence and coexistence of synthetic cannabinoids in “herbal high” products in Poland. Forensic Toxicol 31:21–30CrossRefGoogle Scholar
  8. 8.
    Mauler F, Mittendorf J, Horváth E, De Vry J (2002) Characterization of the diarylether sulfonylester (−)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J Pharmacol Exp Ther 302:359–368PubMedCrossRefGoogle Scholar
  9. 9.
    EMCDDA (2009) Thematic papers: understanding the “spice” phenomenon. European Monitoring Centre for Drugs and Drug Addiction, LisbonGoogle Scholar
  10. 10.
    Malan TP Jr, Ibrahim MM, Lai J, Vanderah TW, Makriyannis A, Porreca F (2003) CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol 3:62–67PubMedCrossRefGoogle Scholar
  11. 11.
    Clayton N, Marshall FH, Bountra C, O’Shaughnessy CT (2002) CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 96:253–260PubMedCrossRefGoogle Scholar
  12. 12.
    Quartilho A, Mata HP, Ibrahim MM, Vanderah TW, Porreca F, Makriyannis A, Malan TP Jr (2003) Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology 99:955–960PubMedCrossRefGoogle Scholar
  13. 13.
    Choi H, Heo S, Kim E, Hwang BY, Lee C, Lee J (2013) Identification of (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone and its 5-pentyl fluorinated analog in herbal incense seized for drug trafficking. Forensic Toxicol 31:86–92CrossRefGoogle Scholar
  14. 14.
    Aung MM, Griffin G, Huffman JW, Wu MJ, Keel C, Yang B, Showalter VM, Abood ME, Martin BR (2000) Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding. Drug Alcohol Depend 60:133–140PubMedCrossRefGoogle Scholar
  15. 15.
    Huffman JW, Szklennik PV, Almond A, Bushell K, Selley DE, He H, Cassidy MP, Wiley JL, Martin BR (2005) 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett 15:4110–4113PubMedCrossRefGoogle Scholar
  16. 16.
    Weissman A, Milne GM, Melvin LS Jr (1982) Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol. J Pharmacol Exp Ther 223:516–523PubMedGoogle Scholar
  17. 17.
    Harris CR, Brown A (2013) Synthetic cannabinoid intoxication: a case series and review. J Emerg Med 44:360–366PubMedCrossRefGoogle Scholar
  18. 18.
    Patton AL, Chimalakonda KC, Moran CL, McCain KR, Radominska-Pandya A, James LP, Kokes C, Moran JH (2013) K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. J Forensic Sci. doi: 10.1111/1556-4029.12216 PubMedGoogle Scholar
  19. 19.
    Park Y, Lee C, Lee H, Pyo J, Jo J, Lee J, Choi H, Kim S, Hong RS, Park Y, Hwang BY, Choe S, Jung JH (2013) Identification of a new synthetic cannabinoid in a herbal mixture: 1-butyl-3-(2-methoxybenzoyl)indole. Forensic Toxicol 31:187–196CrossRefGoogle Scholar
  20. 20.
    Choi H, Heo S, Choe S, Yang W, Park Y, Kim E, Chung H, Lee J (2013) Simultaneous analysis of synthetic cannabinoids in the materials seized during drug trafficking using GC–MS. Anal Bioanal Chem 405:3937–3944PubMedCrossRefGoogle Scholar
  21. 21.
    Nakajima J, Takahashi M, Nonaka R, Seto T, Suzuki J, Yoshida M, Kanai C, Hamano T (2011) Identification and quantitation of a benzoylindole (2-methoxyphenyl)(1-pentyl-1H-indole-3-yl)methanone and a naphthoylindole 1-(5-fluoropentyl-1H-indol-3-yl)-(naphthalene-1-yl)methanone (AM-2201) found in illegal products obtained via the Internet and their cannabimimetic effects evaluated by in vitro [35S]GTPγS binding assays. Forensic Toxicol 29:132–141CrossRefGoogle Scholar
  22. 22.
    Frost JM, Dart MJ, Tietje KR, Garrison TR, Grayson GK, Daza AV, El-Kouhen OF, Yao BB, Hsieh GC, Pai M, Zhu CZ, Chandran P, Meyer MD (2010) Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB2 cannabinoid receptor activity. J Med Chem 53:295–315PubMedCrossRefGoogle Scholar
  23. 23.
    Pace JM, Tietje K, Dart MJ, Meyer MD (2006) 3-Cycloalkylcarbonyl indoles as cannabinoid receptor ligands. Published in 2006-06-29, assigned to Abbott LaboratoriesGoogle Scholar
  24. 24.
    Yao BB, Hsieh G, Daza AV, Fan Y, Grayson GK, Garrison TR, El Kouhen O, Hooker BA, Pai M, Wensink EJ, Salyers AK, Chandran P, Zhu CZ, Zhong C, Ryther K, Gallagher ME, Chin CL, Tovcimak AE, Hradil VP, Fox GB, Dart MJ, Honore P, Meyer MD (2009) Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. J Pharmacol Exp Ther 328:141–151PubMedCrossRefGoogle Scholar
  25. 25.
    Uemura N, Fukaya H, Kanai C, Yoshida M, Nakajima J, Takahashi M, Suzuki J, Moriyasu T, Nakae D (2013) Identification of a synthetic cannabinoid A-836339 as a novel compound found in a product. Forensic Toxicol. doi: 10.1007/s11419-013-0201-x Google Scholar
  26. 26.
    Shin MH (2012) Improvement of drug designation system–introduction of emergency procedure and analogue system (in Korean). J FDC Regulatory Sci 7:13–19Google Scholar

Copyright information

© Japanese Association of Forensic Toxicology and Springer Japan 2013

Authors and Affiliations

  • Heesun Chung
    • 1
  • Hyeyoung Choi
    • 2
  • Sewoong Heo
    • 2
  • Eunmi Kim
    • 2
  • Jaesin Lee
    • 2
  1. 1.Graduate School of Analytical Science and TechnologyChungnam National UniversityDaejeonSouth Korea
  2. 2.National Forensic ServiceSeoulSouth Korea

Personalised recommendations